SBIR-STTR Award

Activated Hexosamines from Chitin for Production of Important Oligosaccharides
Award last edited on: 9/26/14

Sponsored Program
SBIR
Awarding Agency
NIH : NIGMS
Total Award Amount
$168,163
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Leila Aminova

Company Information

zuChem Inc

2225 West Harrison Street Suite F
Chicago, IL 60612
   (312) 997-2150
   info@zuchem.com
   www.zuchem.com
Location: Multiple
Congr. District: 07
County: Cook

Phase I

Contract Number: 1R43GM110916-01
Start Date: 9/1/14    Completed: 2/28/15
Phase I year
2014
Phase I Amount
$168,163
UDP-GlcNAc and UDP-GalNAc comprise the core structures of glycans in glycoproteins and glycolipids. Oligosaccharides containing N-acetyl-hexosamines involved in various biological process, including microbial infection, toxin entry, cancer cell metastasis. They are the key building blocks for human milk oligosaccharides, blood antigens, and other important oligosaccharides. Oligosaccharides with core structures containing these sugars are needed for investigating cell signaling processes and metabolic regulation; these oligosaccharides have intensively been investigated as antimicrobial agents and prospective anticancer vaccines. The limiting factor in the development of these applications is the high production cost and low availability of the UDP-GlcNAc and UDP-GalNAc building blocks. Cost factors include a lack of effective enzymatic systems for making these activated sugars, extensive purification steps, and the cost of nucleoside triphosphates. Here we propose to develop a technology for the large-scale production of two main components of human milk oligosaccharides and other oligosaccharides, UDP-GlcNAc and UDP-GalNAc, from one of most abundant biopolymers in nature, chitin. In Phase I we will select set of enzyme that will enable effective conversion of chitin to GlcNAc-1-phosphate, using zuChem proprietary enzymes will transform to UDP-GlcNAc, UDP- GalNAc, globotetraose and lacto-N-triose II and analyze economic efficiency of this conversion. In Phase II we will optimize reaction condition for large scale production of activated N-acetylhexosamine, expand our library of glycosiltransferases for production of important oligosaccharides: globotetraose, core milk oligosaccharides Lacto-N-tetraose, Lacto-N-neo-tetraose and they derivatives. Finally in Phase III commercialization we will sell UDP- GlcNAc/GalNAc and oligosaccharides.

Thesaurus Terms:
Acetylgalactosamine;Acetylglucosamine;Anabolism;Anti-Cancer Therapeutic;Anti-Infective Agents;Antibiotics;Antigens;Antimicrobial Drug;Bacteria;Biological Process;Biopolymers;Blood;Blood Groups;Blood Typing Procedure;Cancer Cell;Cell Signaling Process;Chitin;Chitinase;Cloning;Commercialization;Cost;Cost Effective;Coupling;Development;Economics;Enzymes;Epimerase;Epitopes;Escherichia Coli;Expression Vector;Food Supplements;Globotetraose;Globotriose;Glycolipids;Glycoproteins;Glycosyltransferase;Goals;Health;Hexosamines;Housing;Human;Human Milk;Improved;Infection;Inorganic Phosphate;Interest;Lacto-N-Neotetraose;Lactose;Large Scale Production;Libraries;Lipids;Marketing;Metabolic;Methods;Microbial;Milk;Modification;N Acetylhexosamine;N-Acetylglucopyranosylamine;Nature;Neoplasm Metastasis;Nucleoside Triphosphate;Nutrition;Oligosaccharides;Overexpression;Phase;Phosphorylase Kinase;Phosphotransferases;Polymers;Polysaccharides;Production;Prospective;Proteins;Public Health Relevance;Reaction;Recombinants;Regulation;Research;Scale Up;Structure;Sugar;Sugar Nucleotide;System;Techniques;Technology;Testing;Therapeutic;Therapeutic Uses;Tool;Toxin;Trioses;Uridine;Uridine Diphosphate Galactose;Vaccines;

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----